Want to see ENSC full AI Analyst Report?
ENSC Stock Chart & Stats
$0.26
<$0.01(0.08%)
At close: 4:00 PM EDT
$0.26
<$0.01(0.08%)
Day’s Range― - ―
52-Week Range$0.23 - $2.75
Previous CloseN/A
Volume225.00K
Average Volume (3M)89.63K
Market Cap
$7.78M
Enterprise Value$2.97
Total Cash (Recent Filing)$676.70K
Total Debt (Recent Filing)$196.84K
Price to Earnings (P/E)―
Beta2.19
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding19,456,795
10 Day Avg. Volume106,568
30 Day Avg. Volume89,627
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.73
Price to Sales (P/S)0.00
P/FCF Ratio-0.30
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Orphan-designated Pipeline Asset (CY-200)Orphan Drug Designation gives CY-200 regulatory and commercial advantages (smaller trials, potential exclusivity) that materially improve the probability-to-market and commercial economics for a neuroplastogenic pain asset. This durable benefit supports a clearer development path into registrational programs and strategic partnering opportunities.
Up To $77M Of Structured Financing To Fund DevelopmentThe combined $17.1M pre-acquisition cash plus an initial private placement and a milestone-linked follow-on (totaling up to ~$77M) provides multi-period funding explicitly aimed at carrying CY-200 through Phase 2 and toward registrational readiness. That materially reduces immediate runway pressure and underpins longer-term clinical execution contingent on milestone achievement.
Proprietary Abuse-deterrent Platforms (TAAP, MPAR)Ensysce’s TAAP and MPAR technologies represent durable, platform-level IP focused on abuse-deterrence and overdose protection for controlled substances. These platforms create product differentiation, licensing and partnering leverage, and align with structural regulatory and payer incentives toward safer opioid formulations, supporting long-term commercial optionality.
Bears Say
Persistent Cash BurnNegative operating and free cash flow of roughly -$9.6M TTM indicates the company cannot self-fund operations or clinical development. Sustained cash burn forces recurring capital raises, increases dilution risk, and constrains strategic flexibility to advance multiple programs concurrently unless financings materialize as planned.
Deep Unprofitability And Falling RevenueSteep revenue decline and highly negative gross and net margins show the cost base far exceeds current revenue. This structural unprofitability raises the bar for future break-even, increases reliance on external capital, and heightens execution risk for clinical programs if revenue or financing expectations are not met.
Complex Capital Structure And Dilution/control RiskThe stock-for-stock acquisition and issuance of convertible Series C preferred with automatic conversion mechanics create a large ownership shift and potential governance changes. Such structure concentrates ownership with former Cy stakeholders, may dilute existing common holders substantially upon conversion, and leaves control tied to financing and approval contingencies.
Ensysce Biosciences News
ENSC FAQ
What was Ensysce Biosciences’s price range in the past 12 months?
Ensysce Biosciences lowest stock price was $0.23 and its highest was $2.75 in the past 12 months.
What is Ensysce Biosciences’s market cap?
Ensysce Biosciences’s market cap is $7.78M.
When is Ensysce Biosciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Ensysce Biosciences’s earnings last quarter?
Currently, no data Available
Is Ensysce Biosciences overvalued?
According to Wall Street analysts Ensysce Biosciences’s price is currently Overvalued.
Does Ensysce Biosciences pay dividends?
Ensysce Biosciences does not currently pay dividends.
What is Ensysce Biosciences’s EPS estimate?
Ensysce Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ensysce Biosciences have?
Ensysce Biosciences has 19,456,795 shares outstanding.
What happened to Ensysce Biosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Ensysce Biosciences?
Currently, no hedge funds are holding shares in ENSC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ensysce Biosciences
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
Technical Analysis
Ownership Overview
―
Insiders
0.17% Mutual Funds
1.30% Other Institutional Investors
98.46% Public Companies and
Individual Investors